- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05248672
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers (COG0107)
April 10, 2023 updated by: Cognition Therapeutics
A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers
This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.
Study Overview
Detailed Description
Open label study to assess PK in 36 older healthy volunteers.
Subjects will be screened 35 days prior dose to determine eligibility.
On day -1 subjects will be admitted to the clinical research unit and on day 1 will be randomized to receive one of the following doses: 150 mg BID, 150 mg QD or 300 mg QD in the fed state.
Subjects will be confined in the Clinical Research Unit where they will continue to receive study drug and complete safety assessments, PK and CSF draws, until day 16 when they will be discharged.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
DeLand, Florida, United States, 32720
- Accel Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and Women 50-80 years of age, inclusively
- In good health as determined by the Investigator with no clinically significant abnormalities
- Weight between 50.0 and 100.0 kg, inclusive at Screening
- No suicidal ideation
- No active depression
- Living independently at home or in a community setting
- Able to swallow CT1812 capsule or capsules
- Non-smoker with no history of using tobacco or any nicotine-containing products
- Subjects with negative serology for HIV, Hepatitis B, and C
- Negative results for drugs of abuse, cotinine, and alcohol
- Negative test results for COVID-19
- Willing to comply with Clinical Pharmacology Unit's COVID-19 policies
Exclusion Criteria:
- Any chronic medical condition which, in the opinion of the investigator, might pose a safety risk to the subject or interfere with study interpretation
- Subject with active or recent infection requiring antibiotic therapy
- Medical history of vasculitis or any autoimmune disease
- Any recent hospitalization
- Subjects living in a continuous care nursing facility
- Any contraindication to a lumbar puncture
- Subjects with self-reported history of major depression
- History of diabetes
- Intake of drugs or substances potentially involved in clinically significant induction or inhibition of CYP3A4 or P-gp mediated drug interactions with CT1812
- Intake of investigational drug prior to study drug administration on Day 1
- Participation in an investigational device study prior to study drug administration on Day 1
- Grapefruit, grapefruit juice, and Seville oranges/juice must be avoided within 14 days prior to dosing and throughout the course of the study
- Suspected or known drug or alcohol abuse,
- Excessive consumption of coffee, tea, cola, or other caffeinated beverages
- Loss or donation of blood; nation of bone marrow or peripheral stem cells; or donation of plasma
- Venous access considered inadequate; history or evidence of adverse symptoms associated with phlebotomy or blood donation
- Suspected or known allergy to any component of the study treatments
- Employee or family member of the Investigator, study site personnel, or Sponsor
- A subject with any condition that, in the opinion of the Investigator, makes the subject unsuitable for study participation will be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 150 mg QD
CT1812 150 mg QD
|
Study Drug
|
Experimental: 150 mg BID
CT1812 150 mg BID
|
Study Drug
|
Experimental: 300 mg QD
CT1812 300 mg QD
|
Study Drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
Cmax: Maximum observed plasma concentration occurring at Tmax
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
Tmax: The first time to maximum observed concentration sampled during a dosing interval.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
Ctau: Concentration at the end of the dosing interval (12 hr for BID group; 24 hr for QD group).
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
AUC 0-12h: Area under the concentration-time curve (AUC) from time 0 to 12 hours post-dose.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
AUC 0-24h: AUC from time 0 to 24 hours post-dose.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
AUC 0-last: AUC from time 0 to the time of the last measurable concentration at 48 and 72 hours as applicable.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
AUC 0-inf: Area under the concentration-time curve (AUC) from time 0 extrapolated to infinity, calculated using the observed value of the last non-zero concentration.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
AUC_%Extrap: Percent of AUC0-inf contributed by extrapolation beyond AUC0-last.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
λz : Terminal elimination phase rate constant.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in plasma
Time Frame: Day 13 and 15.
|
t½: Terminal phase half-life.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Cmax - Maximum observed plasma concentration occurring at Tmax.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Tmax -The first time to maximum observed concentration sampled during a dosing interval.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Cavg,ss - Average plasma concentration at steady-state interval.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Ctau-Concentration at the end of the dosing interval (12 hr for BID group; 24 hr for QD group).
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Fluctuation (%) - Fluctuation (%) between maximum and minimum concentrations over the steady-state dosing interval.
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
AUC-0-tau - Area under the concentration-time curve from time 0 to the end of the dosing interval (0-12 for the BID group; 0 - 24 for the QD groups) .
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
λz- Terminal elimination phase rate constant
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
t½ - Terminal phase half-life
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
AUCcum- Accumulation ratio in AUC, calculated as AUC0-tau,ss/AUC0-tau,D1
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Ctau,cum- Accumulation ratio in Ctau, calculated as Ctau,ss/Ctau,D1
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).
Time Frame: Day 13 and 15.
|
Cmax,cum - Accumulation ratio in Cmax, calculated as Cmax,ss/Cmax,D1
|
Day 13 and 15.
|
Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF)- CSF/plasma ratio
Time Frame: Day 13 and 15.
|
CSF/plasma ratio - Pre-dose on Day 13 and 3h (±15 min) post-dose on Day 15
|
Day 13 and 15.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Anthony Caggiano, MD, Cognition Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2022
Primary Completion (Actual)
June 1, 2022
Study Completion (Actual)
June 1, 2022
Study Registration Dates
First Submitted
February 10, 2022
First Submitted That Met QC Criteria
February 10, 2022
First Posted (Actual)
February 21, 2022
Study Record Updates
Last Update Posted (Actual)
April 12, 2023
Last Update Submitted That Met QC Criteria
April 10, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COG0107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on CT1812
-
Cognition TherapeuticsNational Institute on Aging (NIA)CompletedAlzheimer DiseaseNetherlands
-
Cognition TherapeuticsNational Institute on Aging (NIA)RecruitingDementia With Lewy BodiesUnited States
-
Cognition TherapeuticsCompleted
-
Cognition TherapeuticsNational Institute on Aging (NIA)Active, not recruitingMild to Moderate Alzheimer's DiseaseUnited States, Australia, Netherlands, Czechia, Spain
-
Cognition TherapeuticsNational Institute on Aging (NIA)CompletedAlzheimer DiseaseUnited States
-
Cognition TherapeuticsNational Institute on Aging (NIA)Completed
-
Cognition TherapeuticsNational Institute on Aging (NIA); Alzheimer's Clinical Trials ConsortiumRecruitingEarly Alzheimer's DiseaseUnited States
-
Cognition TherapeuticsRecruitingAge-Related Macular DegenerationUnited States
-
Cognition TherapeuticsCompleted
-
Cognition TherapeuticsCompleted